Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: A systematic literature review

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 866-873

  Boland, J W ^a   McWilliams, K ^b   Ahmedzai, S H ^c   Pockley, A G ^d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

immunity; morphine; neoplasms; NK cells; opioids; T cells

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 2; MORPHINE; OPIATE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CHRONIC PAIN; DISEASE FREE SURVIVAL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; LONG TERM EXPOSURE; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW;

ANALGESICS, OPIOID; HUMANS; IMMUNE SYSTEM; NEOPLASMS; PAIN;

EID: 84906935029     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.384     Document Type: Review

References (61)

1. Afsharimani B, Cabot P, Parat MO (2011) Morphine and tumor growth and metastasis. Cancer Metast Rev 30(2): 225-238.
2. Ahmedzai SH (2013) Personalized medicine-one size fits one: tailoring pain therapy to individuals' needs. J Pain Palliat Care Pharmacother 27: 83-85.
3. Boland JW, Foulds GA, Ahmedzai SH, Pockley AG (2013) A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function. BMJ Support Palliat Care; e-pub ahead of print 27 December 2013; doi:10.1136/bmjspcare-2013-000573.
4. Borner C, Kraus J, Bedini A, Schraven B, Hollt V (2008) T-cell receptor/ CD28-mediated activation of human T lymphocytes induces expression of functional mu-opioid receptors. Mol Pharmacol 74: 496-504.
5. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Hollt V, Kraus J (2009) Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J Immunol 183: 882-889.
6. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK (2011) Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol 29: 4769-4775.
7. Budd K (2006) Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother 60: 310-317.
8. Colvin LA, Fallon MT, Buggy DJ (2012) Cancer biology, analgesics, and anaesthetics: is there a link? Br J Anaesth 109: 140-143.
9. Condevaux F, Guichard J, Forichon A, Aujoulat M, Descotes J (2001) Compared effects of morphine and nickel chloride on NK cell activity in vitro in rats and monkeys. J Appl Toxicol 21: 431-434.
10. Fecho K, Maslonek KA, Dykstra LA, Lysle DT (1996) Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J Pharmacol Exp Ther 277: 633-645.
11. Forget P, Collet V, Lavand'homme P, De Kock M (2010) Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol 27: 233-240.
12. Foulds GA, Radons J, Kreuzer M, Multhoff G, Pockley AG (2013) Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol 3: 1-17.
13. Franchi S, Moretti S, Castelli M, Lattuada D, Scavullo C, Panerai AE, Sacerdote P (2012) Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav Immun 26: 480-488.
14. Gach K, Wyrebska A, Fichna J, Janecka A (2011) The role of morphine in regulation of cancer cell growth. Naunyn-Schmiedeberg's Archiv Pharmacol 384: 221-230.
15. Galizia G, Gemei M, Orditura M, Romano C, Zamboli A, Castellano P, Mabilia A, Auricchio A, De Vita F, Del Vecchio L, Lieto E (2013) Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg 17: 1809-1818.
16. Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P (2002) The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol 129: 18-24.
17. Glattard E, Welters ID, Lavaux T, Muller AH, Laux A, Zhang D, Schmidt AR, Delalande F, Laventie BJ, Dirrig-Grosch S, Colin DA, Van Dorsselaer A, Aunis D, Metz-Boutigue MH, Schneider F, Goumon Y (2010) Endogenous morphine levels are increased in sepsis: a partial implication of neutrophils. PLoS One 5: e8791.
18. Hashiguchi S, Morisaki H, Kotake Y, Takeda J (2005) Effects of morphine and its metabolites on immune function in advanced cancer patients. J Clin Anesth 17: 575-580.
19. Heaney A, Buggy DJ (2012) Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 109(Suppl 1): i17-i28.
20. House RV, Thomas PT, Bhargava HN (1995) In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. Immunol Lett 46: 117-124.
21. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker EM, Jekich BM, Wieseler JL, Somogyi AA, Martin D, Poole S, Judd CM, Maier SF, Watkins LR (2008) Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 22: 1178-1189.
22. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR (2010) Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24: 83-95.
23. Irwin M, Hauger RL, Brown M, Britton KT (1988) CRF activates autonomic nervous system and reduces natural killer cytotoxicity. Am J Physiol 255: R744-R747.
24. Jacobs R, Karst M, Scheinichen D, Bevilacqua C, Schneider U, Heine J, Schedlowski M, Schmidt RE (1999) Effects of fentanyl on cellular immune functions in man. Int J Immunopharmacol 21: 445-454.
25. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181.
26. Kelly E, Bailey CP, Henderson G (2008) Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153(Suppl 1): S379-S388.
27. Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Tanaka K, Nishio K, Nakagawa K (2011) Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. Anticancer Res 31: 4561-4568.
28. Martucci C, Panerai AE, Sacerdote P (2004) Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110: 385-392.
29. Mellon RD, Bayer BM (1998) Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res 789: 56-67.
30. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
31. Molitor TW, Murtaugh MP, Click RE, Gekker G, Chao C, Peterson PK (1992) Functional alterations of swine peripheral blood mononuclear cells by methadone. J Leukoc Biol 51: 124-128.
32. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, Fraumeni Jr JF, Curtis RE (2013) Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 121: 2996-3004.
33. Nüssler NC, Stange BJ, Petzold M, Nussler AK, Glanemann M, Guckelberger O (2007) Reduced NK-cell activity in patients with metastatic colon cancer. EXCLI J 6: 1-9.
34. Page GG (2003) The immune-suppressive effects of pain. Adv Exp Med Biol 521: 117-125.
35. Page GG (2005) Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage 29: S25-S31.
36. Page GG, Blakely WP, Ben-Eliyahu S (2001) Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 90: 191-199.
37. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27: 5944-5951.
38. Palm S, Lehzen S, Mignat C, Steinmann J, Leimenstoll G, Maier C (1998) Does prolonged oral treatment with sustained-release morphine tablets influence immune function? Anesth Analg 86: 166-172.
39. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8: 287-313.
40. Provinciali M, Di Stefano G, Raffaeli W, Pari G, Desiderio F, Fabris N (1991) Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. Int J Neurosci 59: 127-133.
41. Provinciali M, Di Stefano G, Stronati S, Raffaeli W, Pari G, Fabris N (1996) Role of prolactin in the modulation of NK and LAK cell activity after short-or long-term morphine administration in neoplastic patients. Int J Immunopharmacol 18: 577-586.
42. Reiman JM, Kmieciak M, Manjili MH, Knutson KL (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 17: 275-287.
43. Sacerdote P (2008) Opioid-induced immunosuppression. Curr Opin Support Palliat Care 2: 14-18.
44. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90: 1411-1414.
45. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 121: 834-840.
46. Saurer TB, Ijames SG, Lysle DT (2006) Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity. J Neuroimmunol 177: 18-26.
47. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B (2004) Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 11: 255-260.
48. Snyder GL, Greenberg S (2010) Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 105: 106-115.
49. Stefano GB, Kream RM, Mantione KJ, Sheehan M, Cadet P, Zhu W, Bilfinger TV, Esch T (2008) Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology. Semin Cancer Biol 18: 199-210.
50. Stein C, Lang LJ (2009) Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 9: 3-8.
51. Terpos E, Berenson J, Raje N, Roodman GD (2014) Management of bone disease in multiple myeloma. Expert Rev Hematol 7: 113-125.
52. Thomas PT, House RV, Bhargava HN (1995) Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen Pharmacol 26: 123-130.
53. Van Der Laan JW, Timmerman H, Van Loveren H (1996) Comparison of the in vivo effects of morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and lungs in rats. Int J Immunopharmacol 18: 401-407.
54. Van Leeuwen MT, Webster AC, Mccredie MR, Stewart JH, Mcdonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM, Grulich AE (2010) Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 340: c570.
55. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S (2002) The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 71: 782-790.
56. West JP, Lysle DT, Dykstra LA (1997) Tolerance development to morphine-induced alterations of immune status. Drug Alcohol Depend 46: 147-157.
57. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. Group, Q. (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529-536.
58. Williams JP, Thompson JP, Mcdonald J, Barnes TA, Cote T, Rowbotham DJ, Lambert DG (2007) Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anesth Analg 105: 998-1005.
59. Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83: 500-508.
60. Yeager MP, Procopio MA, Deleo JA, Arruda JL, Hildebrandt L, Howell AL (2002) Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg 94: 94-99.
61. Yeager MP, Yu CT, Campbell AS, Moschella M, Guyre PM (1992) Effect of morphine and beta-endorphin on human Fc receptor-dependent and natural killer cell functions. Clin Immunol Immunopathol 62: 336-343.